OncLive

What is an overused oncology buzzword❓Experts at #Tandem26 weighed in with their own hot takes. 🤔

@astct.bsky.social @cibmtr.bsky.social #lymsm #leusm #melsm #oncology #hematology #AI

Check out the video here ➡️: www.onclive.com/shorts/overu...

Watch 👀: Amrita Desai, MD, MPH of @ohsunews.bsky.social discusses lifileucel in metastatic melanoma at #Tandem26.

#melsm #oncology @astct.bsky.social @cibmtr.bsky.social

See the whole video here ➡️: onclive.com/shorts/tackl...

WATCH: Kenneth Jin Chang Lim, MBBS, discusses a study investigating the use of dexamethasone prophylaxis to reduce rates of neurotoxicity in myeloma with high ALC after CAR T-cell therapy. @astct.bsky.social @cibmtr.bsky.social #Tandem26 #hematology #mmsm
www.onclive.com/view/dr-lim-...

WATCH: Peter Riedell, MD, discusses the long-term efficacy of tisagenlecleucel in the third-line setting in patients with relapsed/refractory follicular lymphoma. @astct.bsky.social @cibmtr.bsky.social #Tandem26 #lymsm #hematology
www.onclive.com/view/dr-ried...

Thanks to Dr Alfonso Molina, of @stanfordhealthcare.bsky.social, for joining us at #Tandem26 to share findings with Orca-T and allogeneic CAR-T cell therapy in B-ALL! See our site for more from the meeting. @astct.bsky.social @cibmtr.bsky.social #leusm #hematology
www.onclive.com/conference/tct

Thank you to Dr Amrita Desai, of @ohsunews.bsky.social, for stopping by during #Tandem26 to chat about real-world outcomes with lifileucel in melanoma! See our site for more from the meeting. @astct.bsky.social @cibmtr.bsky.social #melsm
www.onclive.com/conference/tct

A huge thanks to Dr Fernando Duarte, who sat down with us at #Tandem26 to discuss the use of allogeneic HCT in MDS in Brazil! Check out our site for more of today's exclusive meeting coverage! @astct.bsky.social @cibmtr.bsky.social #hematology
www.onclive.com/conference/tct

What do you bring with you to every conference❓

Check out how experts at #Tandem26 answered. 😂

@astct.bsky.social @cibmtr.bsky.social #mmsm #lymsm #leusm #oncology
#hematology

Watch the whole video here ➡️: www.onclive.com/shorts/hemat...

Single-Center, Retrospective Data Show Low Rate of Lifileucel Infusion Following Referral in Advanced #Melanoma @astct.bsky.social @cibmtr.bsky.social #tandem2026

www.onclive.com/view/single-...

📊 Long-Term Cilta-Cel Data Show Low Rates of PFS Events in Standard-Risk R/R #Myeloma 🩸🧬
@astct.bsky.social @cibmtr.bsky.social #Tandem2026

www.onclive.com/view/long-te...

Orca-T With Allogeneic CAR T-Cell Therapy Is Safe and Effective in High-Risk B-ALL
#leusm #oncology #Tandem26 @astct.bsky.social @cibmtr.bsky.social
www.onclive.com/view/orca-t-...

The @fda.gov has approved an update to the prescribing information for axi-cel, removing prior Limitations of Use for patients with relapsed/refractory primary central nervous system lymphoma #lymsm #oncology www.onclive.com/view/fda-upd...

What are the biggest developments and challenges in CAR T-cell therapy❓

At #Tandem26 we met with experts Kenneth Lim, MBBS, Peter Riedell, MD, and Nathan Denlinger, DO, to hear their insights.

@astct.bsky.social @cibmtr.bsky.social #oncology #mmsm

See video here ➡️: www.onclive.com/shorts/tct-2...

Bridging Therapy Nonresponse, High Lymphocyte Count Are Associated With Parkinsonism After Cilta-Cel in #Myeloma @astct.bsky.social @cibmtr.bsky.social #Tandem2026

www.onclive.com/view/bridgin...

A rolling submission of a BLA for OST-HER2 has been initiated, seeking approval of the agent for the prevention or delay of recurrence in patients with fully resected pulmonary metastatic osteosarcoma #scmsm #oncology www.onclive.com/view/rolling...

Final Analysis of MOUNTAINEER Strengthens Support for Tucatinib Plus Trastuzumab in HER2+ mCRC #oncology #crc
www.onclive.com/view/final-a...

Frontline Retifanlimab Approaches EU Approval for Advanced Squamous Cell Carcinoma of the Anal Canal
#oncology #GIcancer

www.onclive.com/view/frontli...

Thank you to Dr Nathan Denlinger, of @osucccjames.bsky.social, for stopping by during #Tandem26 to talk about real-world data with CAR T-cell therapy in LBCL!
See our site for more from the meeting! @astct.bsky.social @cibmtr.bsky.social #lymsm #hematology
www.onclive.com/conference/tct

Orca-T With Reduced-Intensity Conditioning Yields Robust Efficacy in Hematologic Malignancies

#leusm #oncology #Tandem26 @astct.bsky.social @cibmtr.bsky.social

www.onclive.com/view/orca-t-...

Ustekinumab Plus Standard Prophylaxis Reduces GVHD in MAC Subgroup @astct.bsky.social @cibmtr.bsky.social
#Tandem2026
www.onclive.com/view/ustekin...

The FDA issued a reminder to underscore the risks associated with DPD deficiency and capecitabine/5-FU use in cancer care #oncology www.onclive.com/view/fda-und...

HARBOR Trial Aims to Further Elucidate Potential Role for Elenestinib in Indolent Systemic Mastocytosis #oncology #hematology

www.onclive.com/view/harbor-...

TRX103 Tr1 Cell Therapy Shows Manageable Safety ✅ and Dose-Dependent Kinetics 📈 After HLA-Mismatched HCT 🩸 in Hematologic Malignancies 🧬
@astct.bsky.social @cibmtr.bsky.social #Tandem2026

Read the full article ⬇️
www.onclive.com/view/trx103-...

The use of prophylactic dexamethasone did not lower the risk of delayed neurotoxicities in patients with multiple myeloma who received cilta-cel.

Read more on these retrospective data presented at #Tandem2026 #mmsm #oncology www.onclive.com/view/prophyl...

Acalabrutinib Delivers Strong Responses With Manageable Toxicities in Steroid-Refractory cGVHD
#oncology #Tandem2026 @astct.bsky.social @cibmtr.bsky.social
www.onclive.com/view/acalabr...

Retrospective data show up-front dose reductions of enfortumab vedotin lowered the risk of treatment interruptions without impeding OS in patients with advanced urothelial cancer receiving first-line enfortumab vedotin plus pembrolizumab #blcsm #oncology #OncClub www.onclive.com/view/enfortu...

WATCH: Mabel Mardones, MD, explains how TROP2-directed ADCs such as Dato-DXd and sacituzumab govitecan are poised to reshape the frontline treatment paradigm in metastatic TNBC #bcsm #oncology www.onclive.com/view/dr-mard...

WATCH 👀: Louis Potters, MD, FASTRO, FABS, FACR, of @northwellhealth.bsky.social discusses the significance of #WorldCancerDay #oncology
See the whole video here 🎥: www.onclive.com/view/dr-pott...

FDA Grants Fast Track Designation to Pelareorep Plus Bevacizumab/FOLFIRI in Second-Line KRAS-Mutant mCRC #oncology #medtwitter #CRC
www.onclive.com/view/fda-gra...

On World Cancer Day, Northwell Highlights a Blueprint for Consistent, System-Wide Cancer Care @northwellhealth.bsky.social #oncology #WorldCancerDay
www.onclive.com/view/on-worl...